Aims of our Clinical Core are to provide access to a large group of patients with sickle cell disease who will be potentially available for collaborative inter-center clinical trials and for the studies of investigators within the Boston Comprehensive Sickle Cell Center. We will also deliver the highest level of patient care available by assuring access to physicians and nurses specially trained in managing hemoglobinopathies who are aware of the most recent advances in sickle cell disease treatment. Three medical centers in Boston, Boston Medical Center, Brigham and Women's Hospital and Children's Hospital, and, the University of Mississippi Medical Center provide access to more than 1600 patients with sickle cell disease. Each component of the Clinical Core is staffed by one or more physicians experienced in the care of patients with sickle cell disease and by a similarly experienced nursing staff. Each clinic has a long and successful record of participation in clinical trials in sickle cell disease.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston Medical Center
United States
Zip Code
Loscalzo, Joseph; Handy, Diane E (2014) Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series). Pulm Circ 4:169-74
Zhao, Yuzheng; Yang, Yi; Loscalzo, Joseph (2014) Real-time assessment of the metabolic profile of living cells with genetically encoded NADH sensors. Methods Enzymol 542:349-67
Barroso, Madalena; Florindo, Cristina; Kalwa, Hermann et al. (2014) Inhibition of cellular methyltransferases promotes endothelial cell activation by suppressing glutathione peroxidase 1 protein expression. J Biol Chem 289:15350-62
Maron, Bradley A; Oldham, William M; Chan, Stephen Y et al. (2014) Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation 130:168-79
Cottrill, Katherine A; Chan, Stephen Y; Loscalzo, Joseph (2014) Hypoxamirs and mitochondrial metabolism. Antioxid Redox Signal 21:1189-201
Maron, Bradley A; Waxman, Aaron B; Opotowsky, Alexander R et al. (2013) Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 112:720-5
Handy, Diane E; Loscalzo, Joseph; Leopold, Jane A (2013) Systems analysis of oxidant stress in the vasculature. IUBMB Life 65:911-20
Nallamshetty, Shriram; Chan, Stephen Y; Loscalzo, Joseph (2013) Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med 64:20-30
Silverman, E K; Loscalzo, J (2013) Developing new drug treatments in the era of network medicine. Clin Pharmacol Ther 93:26-8
Kao, Derrick D; Oldebeken, Scott R; Rai, Anjali et al. (2013) Tumor necrosis factor-?-mediated suppression of dual-specificity phosphatase 4: crosstalk between NF?B and MAPK regulates endothelial cell survival. Mol Cell Biochem 382:153-62

Showing the most recent 10 out of 82 publications